Expression of enhancer of zeste homolog 2 in transitional cell carcinoma of the bladder cell lines and tissues
10.3760/cma.j.issn.1000-6702.2009.05.014
- VernacularTitle:EZH2基因在膀胱移行细胞癌细胞株和癌组织标本中的表达及意义
- Author:
Ji LU
;
Xiaoqing WANG
;
Zhihua LU
;
Yuchuan HOU
;
Qihui CHEN
;
Yan WANG
;
Fengming JIANG
;
Chunxi WANG
- Publication Type:Journal Article
- Keywords:
Gene expression;
Bladder neoplasms;
Enhancer of zeste homolog 2 geneDOI: 10. 3760/cma.j.issn. 1000-6702. 2009.05. 014
- From:
Chinese Journal of Urology
2009;30(5):332-335
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the expression of enhancer of zeste homolog 2 (EZH2) gene in transitional cell carcinoma (TCC) of the bladder celt lines, carcinoma tissues and normal bladder tis-sues and to evaluate the roles of EZH2 in the development and progression of bladder carcinoma. Methods RT-PCR, Western-blot and immunocytochemistry were used to analyze the expression of EZH2 of the bladder cell lines (T24, EJ, MGH-U1, BIU-87). The prostate cancer cell line PC-3M was used as an EZH2-positive cell line. EZH2 gene expressions in 45 cases of bladder carcinoma and 12 cases of normal bladder mueosa were detected by RT-PCR. Of cancer cases, 31 were superficial tumors and 14 were invasive tumors; 13 were G1, 21 were G2 and 11 were G3. Results EZH2 was detected in the 4 TCC cell lines. The EZH2 expression rate of TCC (82.2%) was significantly higher than that of normal bladder tissues (8.3%, P<0.05). The expression rate in superficial tumors was 74.2% and in invasive tumors was 100.0%, but there was no significant difference (P>0.05). The expression rates increased with tumor cell grade increase, but there was no significant difference (P> 0.05). Conclusions EZH2 could play an important role in the development and progression of blad-der carcinoma. It could be used as a potential gene therapy target of bladder cancer.
